LGND Ligand Pharmaceuticals Inc - Class B

  1. Stocks
  2. Healthcare
  3. NASDAQ: LGND

Price (delayed)

$308.79

Market cap

$6.18B

P/E Ratio

116.52

Dividend/share

N/A

EPS

$2.65

Enterprise value

$7.27B

?
Relative Growth: Rel. Growth: 26
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 57

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model ...

Highlights
Ligand Pharmaceuticals's net income has plunged by 74% from the previous quarter but it has increased by 6% YoY
Ligand Pharmaceuticals's EPS has shrunk by 74% QoQ but it has increased by 15% YoY
The debt has soared by 156% YoY and by 2% from the previous quarter
LGND's P/E is 128% above its last 4 quarters average of 51.0
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ligand.com
Peers: AMGN MRK BMY LLY

Key stats

What are the main financial stats of LGND

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
-2.37%
1 week
0.85%
1 month
1.73%
1 year
53.42%
YTD
63.32%
QTD
-1.15%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$253.83M
Gross profit
$241.7M
Operating income
$24.04M
Net income
$51.46M
Gross margin
95.2%
Net margin
20.3%
The company's operating income has shrunk by 75% QoQ but it rose by 34% YoY
Ligand Pharmaceuticals's net income has plunged by 74% from the previous quarter but it has increased by 6% YoY
Ligand Pharmaceuticals's operating margin has shrunk by 71% QoQ but it has increased by 32% YoY
The net margin has plunged by 70% from the previous quarter but it has grown by 5% YoY

Price vs fundamentals

How does LGND's price correlate with its fundamentals

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
LGND P/E details
P/E
116.52
P/B
6.4
P/S
24.28
EV/EBIT
119.37
EV/EBITDA
73.86
EV/Sales
28.64
LGND's P/E is 128% above its last 4 quarters average of 51.0
Ligand Pharmaceuticals's EPS has shrunk by 74% QoQ but it has increased by 15% YoY
LGND's P/B is 129% higher than its 5-year quarterly average of 2.8 and 23% higher than its last 4 quarters average of 5.2
The price to sales (P/S) is 113% higher than the 5-year quarterly average of 11.4 and 31% higher than the last 4 quarters average of 18.6
The revenue has declined by 13% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's ROIC has plunged by 78% from the previous quarter and by 64% YoY
The ROA has shrunk by 77% QoQ and by 40% YoY
The company's return on equity has shrunk by 74% QoQ and by 9% YoY
Ligand Pharmaceuticals's return on sales has shrunk by 71% QoQ and by 10% YoY

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
The company's total assets is 75% higher than its total liabilities
Ligand Pharmaceuticals's total liabilities has surged by 142% YoY and by 4.7% QoQ
LGND's current ratio has dropped by 96% since the previous quarter and by 95% year-on-year
The debt is 20% more than the equity
The debt has soared by 156% YoY and by 2% from the previous quarter
The debt to equity has soared by 155% YoY and by 2.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.